Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hikma Pharmaceuticals PLC (HIK.L)
GBp1,495.00
-1.00 (-0.07%)
GB LSE Healthcare Drug Manufacturers - Specialty & Generic
Address
1 New Burlington Place W1S 2HR
London, GB
London, GB
CEO
Said Samih Taleb Darwazah
Website
hikma.com
IPO
2005-11-01
ISIN GB00B0LCW083
Also trades on
London Stock Exchange · HIK.L (GBp)
Other OTC · HKMPF (USD)
Other OTC · HKMPY (USD)
Description
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
GBp1,495.00
-1.00 (-0.07%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
821.7K
Beta
0.65
Float Shares
151.33M
Free Float %
71.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07% | -0.07% | +5.54% | +12.33% | -5.02% | -4.77% | -31.03% | -17.91% | -39.38% | -35.77% | +418.80% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1,495.00
DCF (Unlevered)
3,339.52
+123.4%
DCF (Levered)
3,994.82
+167.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
91% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
3.54
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+9.4% ★ Q4'25: +17.3% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+14.3% Q4'25: +184.6% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.1% Q4'25: +6.0% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+18.6% ★ Q4'25: +18.0% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.8% ★ Q4'25: +23.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.4% ★ Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.93× Q4'25: 1.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 7 EPS Ana. |
Dec 2027 9 Rev. Ana. 7 EPS Ana. |
Dec 2028 8 Rev. Ana. 5 EPS Ana. |
Dec 2029 7 Rev. Ana. 1 EPS Ana. |
Dec 2030 7 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
262.22M
est: 255.78M (+2.5%)
|
317.02M
est: 323.01M (-1.9%)
|
448.80M
est: 446.36M (+0.5%)
|
580.66M
est: 539.54M (+7.6%)
|
636.88M
est: 643.34M (-1.0%)
|
730.94M
est: 739.55M (-1.2%)
|
918.03M
est: 904.81M (+1.5%)
|
1.11B
est: 1.12B (-1.1%)
|
1.37B
est: 1.38B (-1.2%)
|
1.49B
est: 1.50B (-0.5%)
|
1.44B
est: 1.45B (-1.0%)
|
1.95B
est: 1.92B (+1.4%)
|
1.94B
est: 1.92B (+0.6%)
|
2.07B
est: 2.21B (-6.2%)
|
2.21B
est: 2.11B (+4.7%)
|
2.34B
est: 2.32B (+0.9%)
|
2.55B
est: 2.51B (+1.9%)
|
2.52B
est: 2.53B (-0.7%)
|
2.88B
est: 3.82B (-24.7%)
|
3.13B
est: 3.09B (+1.3%)
|
3.42B
est: 3.32B (+2.9%)
|
3.47B
3.44B – 3.51B
+4.4% YoY
|
3.63B
3.58B – 3.71B
+4.7% YoY
|
3.80B
3.76B – 3.87B
+4.7% YoY
|
4.00B
3.95B – 4.07B
+5.2% YoY
|
4.17B
4.12B – 4.25B
+4.4% YoY
|
| EBITDA |
79.70M
est: 65.50M (+21.7%)
|
94.35M
est: 90.29M (+4.5%)
|
117.86M
est: 123.13M (-4.3%)
|
113.86M
est: 120.27M (-5.3%)
|
141.10M
est: 100.28M (+40.7%)
|
173.49M
est: 138.18M (+25.6%)
|
154.65M
est: 187.31M (-17.4%)
|
213.00M
est: 152.50M (+39.7%)
|
457.00M
est: 201.33M (+127.0%)
|
481.00M
est: 376.95M (+27.6%)
|
459.00M
est: 408.87M (+12.3%)
|
506.00M
est: 466.78M (+8.4%)
|
554.00M
est: 278.39M (+99.0%)
|
527.00M
est: -555.30M (+194.9%)
|
584.00M
est: 373.07M (+56.5%)
|
631.00M
est: 601.15M (+5.0%)
|
744.00M
est: 643.83M (+15.6%)
|
485.00M
est: 681.52M (-28.8%)
|
791.00M
est: 962.71M (-17.8%)
|
787.00M
est: 778.56M (+1.1%)
|
853.54M
est: 837.39M (+1.9%)
|
874.30M
866.50M – 884.56M
+4.4% YoY
|
915.24M
901.60M – 935.82M
+4.7% YoY
|
958.46M
946.98M – 974.98M
+4.7% YoY
|
1.01B
996.16M – 1.03B
+5.2% YoY
|
1.05B
1.04B – 1.07B
+4.4% YoY
|
| EBIT |
69.62M
est: 50.72M (+37.3%)
|
80.55M
est: 85.62M (-5.9%)
|
94.52M
est: 102.67M (-7.9%)
|
81.35M
est: 111.69M (-27.2%)
|
102.35M
est: 96.23M (+6.4%)
|
126.94M
est: 123.35M (+2.9%)
|
107.65M
est: 165.29M (-34.9%)
|
154.00M
est: 147.05M (+4.7%)
|
395.00M
est: 205.51M (+92.2%)
|
419.00M
est: 360.70M (+16.2%)
|
393.00M
est: 391.10M (+0.5%)
|
401.00M
est: 497.54M (-19.4%)
|
-687.00M
est: 259.50M (-364.7%)
|
428.00M
est: -835.11M (+151.3%)
|
486.00M
est: 357.52M (+35.9%)
|
540.00M
est: 574.26M (-6.0%)
|
600.00M
est: 615.04M (-2.4%)
|
292.00M
est: 651.04M (-55.1%)
|
619.00M
est: 723.32M (-14.4%)
|
608.00M
est: 584.00M (+4.1%)
|
637.09M
est: 629.16M (+1.3%)
|
656.89M
651.03M – 664.60M
+4.4% YoY
|
687.65M
677.41M – 703.11M
+4.7% YoY
|
720.12M
711.50M – 732.54M
+4.7% YoY
|
757.52M
748.45M – 770.58M
+5.2% YoY
|
790.60M
781.13M – 804.23M
+4.4% YoY
|
| Net Income |
43.87M
est: 100.72M (-56.4%)
|
54.52M
est: 55.44M (-1.7%)
|
62.58M
est: 75.31M (-16.9%)
|
57.13M
est: 75.67M (-24.5%)
|
77.68M
est: 68.09M (+14.1%)
|
98.85M
est: 89.32M (+10.7%)
|
80.11M
est: 120.88M (-33.7%)
|
100.00M
est: 99.23M (+0.8%)
|
212.00M
est: 123.58M (+71.5%)
|
278.00M
est: 229.64M (+21.1%)
|
252.00M
est: 274.56M (-8.2%)
|
155.00M
est: 337.04M (-54.0%)
|
-843.00M
est: 154.11M (-647.0%)
|
282.00M
est: -910.74M (+131.0%)
|
486.00M
est: 292.24M (+66.3%)
|
431.00M
est: 522.64M (-17.5%)
|
421.00M
est: 559.75M (-24.8%)
|
188.00M
est: 146.00M (+28.8%)
|
190.00M
est: 360.72M (-47.3%)
|
359.00M
est: 489.52M (-26.7%)
|
410.43M
est: 457.39M (-10.3%)
|
486.47M
423.24M – 549.71M
+6.4% YoY
|
550.94M
507.57M – 594.32M
+13.3% YoY
|
673.55M
460.29M – 689.19M
+22.3% YoY
|
631.30M
621.47M – 645.45M
-6.3% YoY
|
791.26M
778.94M – 808.99M
+25.3% YoY
|
| SGA |
22.61M
est: 51.72M (-56.3%)
|
30.05M
est: 63.14M (-52.4%)
|
43.35M
est: 90.24M (-52.0%)
|
43.21M
est: 129.34M (-66.6%)
|
59.23M
est: 159.54M (-62.9%)
|
76.83M
est: 180.83M (-57.5%)
|
82.17M
est: 234.17M (-64.9%)
|
273.00M
est: 288.39M (-5.3%)
|
311.00M
est: 341.66M (-9.0%)
|
345.00M
est: 336.87M (+2.4%)
|
352.00M
est: 351.59M (+0.1%)
|
429.00M
est: 497.54M (-13.8%)
|
474.00M
est: 389.75M (+21.6%)
|
467.00M
est: 460.23M (+1.5%)
|
487.00M
est: 452.86M (+7.5%)
|
506.00M
est: 487.16M (+3.9%)
|
488.00M
est: 521.74M (-6.5%)
|
509.00M
est: 552.28M (-7.8%)
|
632.00M
est: 736.11M (-14.1%)
|
568.00M
est: 594.33M (-4.4%)
|
577.87M
est: 640.29M (-9.7%)
|
668.51M
662.55M – 676.36M
+4.4% YoY
|
699.82M
689.39M – 715.55M
+4.7% YoY
|
732.86M
724.08M – 745.50M
+4.7% YoY
|
770.93M
761.69M – 784.22M
+5.2% YoY
|
804.59M
794.95M – 818.46M
+4.4% YoY
|
| EPS |
0.30
est: 0.45 (-33.4%)
|
0.33
est: 0.69 (-51.8%)
|
0.37
est: 0.77 (-52.0%)
|
0.30
est: 0.46 (-34.2%)
|
0.41
est: 0.67 (-39.1%)
|
0.51
est: 0.85 (-39.7%)
|
0.41
est: 0.75 (-45.0%)
|
0.51
est: 0.87 (-41.7%)
|
1.08
est: 1.94 (-44.2%)
|
1.40
est: 2.38 (-41.1%)
|
1.27
est: 1.26 (+0.4%)
|
0.67
est: 0.96 (-30.2%)
|
-3.51
est: 0.89 (-496.3%)
|
1.17
est: 1.36 (-14.1%)
|
2.01
est: 1.40 (+44.0%)
|
1.83
est: 1.69 (+8.6%)
|
1.82
est: 1.92 (-5.2%)
|
0.84
est: 1.79 (-53.1%)
|
0.85
est: 1.63 (-48.0%)
|
1.61
est: 2.19 (-26.5%)
|
1.86
est: 2.24 (-16.9%)
|
2.22
1.90 – 2.47
-1.0% YoY
|
2.44
2.28 – 2.67
+10.1% YoY
|
2.63
2.07 – 3.09
+7.8% YoY
|
2.83
2.79 – 2.90
+7.8% YoY
|
3.55
3.50 – 3.63
+25.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.06B
OE per share TTM
4.76
Owner's Yield
32.70%
Maintenance CapEx ratio
11.89%
Maint CapEx / Avg PPE
42.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 121 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P UK Dividend Aristocrats UCITS ETF (Dist) UKDV.L | 3.20% | 4.56M | 0.30% |
| 2 | TD Active Global Equity Growth ETF TGGR.TO | 1.12% | 355.3K | 0.72% |
| 3 | UBS S&P Dividend Aristocrats ESG Elite UCITS ETF USD dis UBUM.DE | 0.95% | 1.95M | 0.30% |
| 4 | Fidelity Europe Quality Income UCITS ETF ACC-EUR FEQD.L | 0.82% | 596.4K | 0.30% |
| 5 | Fidelity Europe Quality Income UCITS ETF INC-EUR FEUI.L | 0.82% | 596.4K | 0.30% |
| 6 | Fidelity Europe Quality Income UCITS ETF ACC-GBP (hedged) FEQP.L | 0.82% | 699.2K | 0.35% |
| 7 | HSBC FTSE 250 UCITS ETF HMCX.L | 0.80% | 539.5K | 0.09% |
| 8 | Invesco FTSE 250 UCITS ETF S250.L | 0.77% | 275.2K | 0.12% |
| 9 | iShares FTSE 250 UCITS ETF MIDD.L | 0.76% | 6.48M | 0.40% |
| 10 | Xtrackers FTSE 250 UCITS ETF 1D XMCX.L | 0.76% | 292.3K | 0.15% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
67.1K
Shares Outstanding
213.03M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mazen Samih Taleb Darwazeh | Executive Vice Chairman & Deputy CEO of MENA | 2M | male |
| Said Samih Taleb Darwazah | Chief Executive Officer | 2M | — |
| Khalid Walid Hussni Al Nabilsi | Deputy CEO of North America and Europe & Director | 32.5K | male |
| Hussein Arkhagha | Chief People Officer | — | male |
| Julie Hill | Senior Vice President of Corporate Quality Compliance/Health & Safety | — | female |
| Patricia Bousfield | Chief Information Officer | — | female |
| Samuel Park | General Counsel | — | male |
| Areb KURDI | VP, Group Financial Controller & Acting CFO | — | male |
| Susan Ringdal | Executive Vice President of Strategic Planning & Global Affairs | — | female |
| Bassam Wael Rushdi Kanaan | Executive Vice President of Corporate Development and M&A | — | male |
| Guy Featherstone | Associate Director of Investor Relations | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HIK.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
